Loading...
Market
Story
London-based Vicebio Secures $100M Series B to Advance Cost-Effective Vaccines
Sep 24, 2024, 09:51 AM
Vicebio, a London-based biotech startup, has successfully raised $100 million in a Series B financing round. The funding will be used to advance its next-generation vaccine candidates into Phase 1 clinical trials. The vaccines aim to be cost-effective and target respiratory viruses such as RSV and hMPV. The financing round saw participation from investors including TCGX, G. Sachs Alternatives, Avoro, venBio, uniQuest, and Medicxi.
View original story
Similar markets
Less than $50M • 25%
$50M to $100M • 25%
$100M to $150M • 25%
More than $150M • 25%
Less than $200M • 25%
$200M - $400M • 25%
$400M - $600M • 25%
More than $600M • 25%
Less than $50 million • 25%
$50 million to $100 million • 25%
$100 million to $150 million • 25%
More than $150 million • 25%
Below $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
Above $3 billion • 25%
Less than $100M • 25%
$100M - $250M • 25%
$250M - $500M • 25%
More than $500M • 25%
Under $100M • 25%
$100M-$200M • 25%
$200M-$300M • 25%
Over $300M • 25%
Below $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
Above $1.5 billion • 25%
Below $3 billion • 25%
$3 billion to $3.5 billion • 25%
$3.5 billion to $4 billion • 25%
Above $4 billion • 25%
Less than $100 million • 25%
$100 million to $200 million • 25%
$200 million to $300 million • 25%
More than $300 million • 25%
Above $1 billion • 25%
Between $750 million and $1 billion • 25%
Between $500 million and $750 million • 25%
Below $500 million • 25%
Under $1 billion • 25%
$1-2 billion • 25%
$2-3 billion • 25%
Over $3 billion • 25%
